Article Details
Retrieved on: 2022-07-14 12:44:54
Tags for this article:
Click the tags to see associated articles and topics
Excerpt
Strengthens balance sheet with non-dilutive capital at an attractive cost ... on Crysvita® (burosumab) for $500 Million to OMERS Capital Markets.
Article found on: www.globenewswire.com
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here